Comparison of the main results of this study and the French study
| . | French study16 (n = 721) . | This study (n = 538) . | ||||
|---|---|---|---|---|---|---|
| IFN-α + LDAC, % . | P . | IFN-α, % . | IFN-α + LDAC, % . | P . | IFN-α, % . | |
| CHR at 6 months | 66 | .003 | 55 | 62 | .11 | 55 |
| MCgR at 12 months | 35 | .001 | 21 | 21 | .012 | 13 |
| MCgR at 24 months | N/A | N/A | N/A | 28 | .003 | 18 |
| 5-year survival | 70 | .02 | 62 | 68 | .77 | 65 |
| . | French study16 (n = 721) . | This study (n = 538) . | ||||
|---|---|---|---|---|---|---|
| IFN-α + LDAC, % . | P . | IFN-α, % . | IFN-α + LDAC, % . | P . | IFN-α, % . | |
| CHR at 6 months | 66 | .003 | 55 | 62 | .11 | 55 |
| MCgR at 12 months | 35 | .001 | 21 | 21 | .012 | 13 |
| MCgR at 24 months | N/A | N/A | N/A | 28 | .003 | 18 |
| 5-year survival | 70 | .02 | 62 | 68 | .77 | 65 |
A difference in favor of IFN-α plus LDAC was confirmed for MCgR, was supported for CHR and was not confirmed for overall survival.
CHR indicates complete hematologic response; N/A, not available. Other abbreviations are explained in Tables 1 and 4.